PRFX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.41
Percentage change 9.23	%

Peers: PTN TTNP EOLS NBIX PCRX ZTS MRK PFE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.29	Insider Own	4.84%	Shs Outstand	3.47M	Perf Week	123.50%
Market Cap	2.86M	Forward P/E	-	EPS next Y	-48.24	Insider Trans	0.00%	Shs Float	0.56M	Perf Month	70.18%
Income	-17.67M	PEG	-	EPS next Q	-7.68	Inst Own	2.47%	Short Float	8.47%	Perf Quarter	83.71%
Sales	0.00M	P/S	-	EPS this Y	53.92%	Inst Trans	157.13%	Short Ratio	0.02	Perf Half Y	-59.44%
Book/sh	-0.59	P/B	-	EPS next Y	38.91%	ROA	-309.43%	Short Interest	0.05M	Perf Year	-93.07%
Cash/sh	4.73	P/C	1.03	EPS next 5Y	-	ROE	-716.67%	52W Range	1.73 - 80.64	Perf YTD	-92.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.81%	ROI	-	52W High	-93.99%	Beta	0.67
Dividend TTM	-	Quick Ratio	0.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	180.80%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	0.61	EPS Y/Y TTM	9.41%	Oper. Margin	-	RSI (14)	53.43	Volatility	79.59% 32.57%
Employees	7	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	48.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-3.64%	Payout	-	Rel Volume	0.20	Prev Close	4.44
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 12	Avg Volume	3.11M	Price	4.85
SMA20	28.75%	SMA50	57.49%	SMA200	-61.25%	Trades		Volume	452,767	Change	9.23%

Nov-20-24 08:30AM	PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial (GlobeNewswire) -25.71%
Nov-07-24 05:00PM	PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire) +7.16%
Oct-25-24 09:25AM	PainReform cut to Hold at Maxim amid changed market dynamics (TipRanks) -8.87%
Sep-11-24 08:30AM	PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 (GlobeNewswire) -10.38%
Sep-10-24 09:46AM	PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds (GlobeNewswire) -33.33%
12:14PM	Loading…
Sep-09-24 12:14PM	Upcoming Stock Splits This Week (September 9 to September 13) Stay Invested (TipRanks)
Aug-21-24 08:30AM	PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures (GlobeNewswire)
Aug-20-24 08:30AM	PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study (GlobeNewswire) -15.20%
Aug-15-24 08:00AM	PainReform Provides Business Update for the Second Quarter of 2024 (GlobeNewswire)
Aug-12-24 09:00AM	PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects (GlobeNewswire)
Aug-07-24 10:00AM	PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses (GlobeNewswire)
Aug-05-24 09:00AM	PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110 (GlobeNewswire) -12.72%
Aug-01-24 08:30AM	PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature (GlobeNewswire)
Jul-24-24 08:30AM	PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing (GlobeNewswire) -6.36%
Jun-26-24 08:00AM	PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 (GlobeNewswire)
07:30AM	Loading…
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -5.49%
May-31-24 04:15PM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-15-24 10:54PM	PRFX Stock Earnings: PainReform Misses EPS for Q1 2024 (InvestorPlace) -6.31%
04:05PM	PainReform Provides Business Update for the First Quarter of 2024 (GlobeNewswire)
May-08-24 08:30AM	PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com (GlobeNewswire) -6.43%
Apr-18-24 02:19PM	PainReform Announces Closing of $4 Million Public Offering (GlobeNewswire)
Apr-16-24 08:00AM	PainReform Announces Pricing of $4 Million Public Offering (GlobeNewswire) -17.42%
Apr-09-24 10:30AM	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions (Benzinga) -13.21%
09:00AM	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions (GlobeNewswire)
Apr-02-24 10:00AM	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug (Benzinga)
08:30AM	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-01-24 08:00AM	PainReform Provides Year-End Business Update (GlobeNewswire) +21.42%
Jan-22-24 08:30AM	PainReform to Present at the Microcap Conference in Atlantic City (GlobeNewswire) -7.37%
Jan-03-24 08:30AM	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief (GlobeNewswire)
Dec-26-23 06:00PM	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds (GlobeNewswire)
04:05PM	Loading…
Nov-15-23 04:05PM	PainReform Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -5.33%
Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire) +44.72%
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-22 07:00AM	PainReform Provides Business Update for the First Quarter of 2022 (GlobeNewswire) +12.84%
Apr-12-22 09:00AM	PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th (GlobeNewswire)
Mar-21-22 09:25AM	PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th (GlobeNewswire) +39.64%
Mar-17-22 08:00AM	PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 (GlobeNewswire) -14.17%
Dec-14-21 08:30AM	PainReform CEO to Participate in the Benzinga All Access Event on December 16th (GlobeNewswire) -5.36%
Nov-22-21 11:58AM	PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today (InvestorPlace)
07:02AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-16-21 08:00AM	PainReform Provides Business Update for the Third Quarter of 2021 (GlobeNewswire) -9.45%
Oct-14-21 08:30AM	PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Aug-16-21 08:00AM	PainReform Provides Business Update for the Second Quarter of 2021 (GlobeNewswire) -5.58%
Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? (Insider Monkey) -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate (Simply Wall St.)
May-13-21 08:15AM	PainReform Provides Business Update for the First Quarter of 2021 (GlobeNewswire) +5.58%
Mar-18-21 09:15AM	PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief (GlobeNewswire) -11.82%
Mar-11-21 10:43AM	PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference (GlobeNewswire)
Mar-08-21 09:00AM	PainReform Announces $6.0 Million Private Placement (GlobeNewswire)
Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations (GlobeNewswire) -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 (ACCESSWIRE)
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer (ACCESSWIRE) +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors (ACCESSWIRE)
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors (ACCESSWIRE)
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 (ACCESSWIRE)
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials (ACCESSWIRE)
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering (ACCESSWIRE)

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PainReform Ltd

Upgrade your FINVIZ experience